Status and phase
Conditions
Treatments
About
To explore the dose and safety of thalidomide for the prevention and treatment of camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP)
Full description
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Prevention cohort 1:
Treatment cohort 2:
Exclusion criteria
Prevention cohort 1:
Treatment cohort 2:
Primary purpose
Allocation
Interventional model
Masking
132 participants in 4 patient groups
Loading...
Central trial contact
Ying Liu, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal